MicroRNAs as Predictive Biomarkers in Patients with Colorectal Cancer Receiving Chemotherapy or Chemoradiotherapy: A Narrative Literature Review
Colorectal cancer (CRC) is one of the most common malignancies and is associated with high mortality rates worldwide. The underlying mechanism of tumorigenesis in CRC is complex, involving genetic, lifestyle-related, and environmental factors. Although radical resection with adjuvant FOLFOX (5-fluor...
Gespeichert in:
| Veröffentlicht in: | Cancers 2023-02, Vol.15 (5), p.1358 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | 1358 |
| container_title | Cancers |
| container_volume | 15 |
| creator | Yang, I-Ping Yip, Kwan-Ling Chang, Yu-Tang Chen, Yen-Cheng Huang, Ching-Wen Tsai, Hsiang-Lin Yeh, Yung-Sung Wang, Jaw-Yuan |
| description | Colorectal cancer (CRC) is one of the most common malignancies and is associated with high mortality rates worldwide. The underlying mechanism of tumorigenesis in CRC is complex, involving genetic, lifestyle-related, and environmental factors. Although radical resection with adjuvant FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) chemotherapy and neoadjuvant chemoradiotherapy have remained mainstays of treatment for patients with stage III CRC and locally advanced rectal cancer, respectively, the oncological outcomes of these treatments are often unsatisfactory. To improve patients' chances of survival, researchers are actively searching for new biomarkers to facilitate the development of more effective treatment strategies for CRC and metastatic CRC (mCRC). MicroRNAs (miRs), small, single-stranded, noncoding RNAs, can post-transcriptionally regulate mRNA translation and trigger mRNA degradation. Recent studies have documented aberrant miR levels in patients with CRC or mCRC, and some miRs are reportedly associated with chemoresistance or radioresistance in CRC. Herein, we present a narrative review of the literature on the roles of oncogenic miRs (oncomiRs) and tumor suppressor miRs (anti-oncomiRs), some of which can be used to predict the responses of patients with CRC to chemotherapy or chemoradiotherapy. Moreover, miRs may serve as potential therapeutic targets because their functions can be manipulated using synthetic antagonists and miR mimics. |
| doi_str_mv | 10.3390/cancers15051358 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10000071</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A741739913</galeid><sourcerecordid>A741739913</sourcerecordid><originalsourceid>FETCH-LOGICAL-c489t-c0a6d74da1cfe44582a781a19e7241e609d7b50a72a4dd01fd750ea78ebe12ba3</originalsourceid><addsrcrecordid>eNptkk1v1DAQhiMEolXpmRuyxIXLtnacxAkXtER8SUupKjhbs_Zkd0o23trOVv0X_GS8u21pK-yD7fEz73jGk2WvBT-RsuGnBgaDPoiSl0KW9bPsMOcqn1RVUzx_sD_IjkO45GlIKVSlXmYHsmo4F2VzmP35Tsa7i7NpYBDYuUdLJtIG2UdyK_C_kz6jgZ1DJBxiYNcUl6x1vfNoIvSs3b2BXaBB2tCwYO0SVy4u0cP6hjm_P3uwdGd8z6bsDLyHXZgZxWSNo8eksSG8fpW96KAPeHy7HmW_Pn_62X6dzH58-dZOZxNT1E2cGA6VVYUFYTosirLOQdUCRIMqLwRWvLFqXnJQORTWctFZVXJMDM5R5HOQR9mHve56nK_QmpSdh16vPaW0b7QD0o9vBlrqhdtosa0kVyIpvLtV8O5qxBD1ioLBvocB3Rh0ruoqwbmQCX37BL10ox9SfluqFKoupPpHLaBHTUPnUmCzFdVTVQglm2andfIfKk2LKzJuwI6S_ZHD6d4hfXQIHrv7JAXX20bSTxopebx5WJt7_q5t5F8hVsa_</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2785178437</pqid></control><display><type>article</type><title>MicroRNAs as Predictive Biomarkers in Patients with Colorectal Cancer Receiving Chemotherapy or Chemoradiotherapy: A Narrative Literature Review</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Yang, I-Ping ; Yip, Kwan-Ling ; Chang, Yu-Tang ; Chen, Yen-Cheng ; Huang, Ching-Wen ; Tsai, Hsiang-Lin ; Yeh, Yung-Sung ; Wang, Jaw-Yuan</creator><creatorcontrib>Yang, I-Ping ; Yip, Kwan-Ling ; Chang, Yu-Tang ; Chen, Yen-Cheng ; Huang, Ching-Wen ; Tsai, Hsiang-Lin ; Yeh, Yung-Sung ; Wang, Jaw-Yuan</creatorcontrib><description>Colorectal cancer (CRC) is one of the most common malignancies and is associated with high mortality rates worldwide. The underlying mechanism of tumorigenesis in CRC is complex, involving genetic, lifestyle-related, and environmental factors. Although radical resection with adjuvant FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) chemotherapy and neoadjuvant chemoradiotherapy have remained mainstays of treatment for patients with stage III CRC and locally advanced rectal cancer, respectively, the oncological outcomes of these treatments are often unsatisfactory. To improve patients' chances of survival, researchers are actively searching for new biomarkers to facilitate the development of more effective treatment strategies for CRC and metastatic CRC (mCRC). MicroRNAs (miRs), small, single-stranded, noncoding RNAs, can post-transcriptionally regulate mRNA translation and trigger mRNA degradation. Recent studies have documented aberrant miR levels in patients with CRC or mCRC, and some miRs are reportedly associated with chemoresistance or radioresistance in CRC. Herein, we present a narrative review of the literature on the roles of oncogenic miRs (oncomiRs) and tumor suppressor miRs (anti-oncomiRs), some of which can be used to predict the responses of patients with CRC to chemotherapy or chemoradiotherapy. Moreover, miRs may serve as potential therapeutic targets because their functions can be manipulated using synthetic antagonists and miR mimics.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers15051358</identifier><identifier>PMID: 36900159</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>5-Fluorouracil ; Antagonists ; Biomarkers ; Biopsy ; Cancer ; Cancer therapies ; Care and treatment ; Chemoradiotherapy ; Chemoresistance ; Chemotherapy ; Colorectal cancer ; Colorectal carcinoma ; Development and progression ; DNA methylation ; Environmental factors ; Feces ; Genetic aspects ; Health aspects ; Kinases ; Literature reviews ; Malignancy ; Management ; Medical prognosis ; Medical research ; Metastases ; Metastasis ; MicroRNA ; MicroRNAs ; miRNA ; Mortality ; Oxaliplatin ; Patients ; Physiological aspects ; Post-transcription ; Radiation therapy ; Radioresistance ; Radiotherapy ; Regulatory approval ; Review ; Survival ; Therapeutic targets ; Translation ; Tumor markers ; Tumor suppressor genes ; Tumorigenesis ; Vascular endothelial growth factor</subject><ispartof>Cancers, 2023-02, Vol.15 (5), p.1358</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c489t-c0a6d74da1cfe44582a781a19e7241e609d7b50a72a4dd01fd750ea78ebe12ba3</citedby><cites>FETCH-LOGICAL-c489t-c0a6d74da1cfe44582a781a19e7241e609d7b50a72a4dd01fd750ea78ebe12ba3</cites><orcidid>0000-0002-7705-2621 ; 0000-0002-1645-2525</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000071/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000071/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36900159$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, I-Ping</creatorcontrib><creatorcontrib>Yip, Kwan-Ling</creatorcontrib><creatorcontrib>Chang, Yu-Tang</creatorcontrib><creatorcontrib>Chen, Yen-Cheng</creatorcontrib><creatorcontrib>Huang, Ching-Wen</creatorcontrib><creatorcontrib>Tsai, Hsiang-Lin</creatorcontrib><creatorcontrib>Yeh, Yung-Sung</creatorcontrib><creatorcontrib>Wang, Jaw-Yuan</creatorcontrib><title>MicroRNAs as Predictive Biomarkers in Patients with Colorectal Cancer Receiving Chemotherapy or Chemoradiotherapy: A Narrative Literature Review</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Colorectal cancer (CRC) is one of the most common malignancies and is associated with high mortality rates worldwide. The underlying mechanism of tumorigenesis in CRC is complex, involving genetic, lifestyle-related, and environmental factors. Although radical resection with adjuvant FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) chemotherapy and neoadjuvant chemoradiotherapy have remained mainstays of treatment for patients with stage III CRC and locally advanced rectal cancer, respectively, the oncological outcomes of these treatments are often unsatisfactory. To improve patients' chances of survival, researchers are actively searching for new biomarkers to facilitate the development of more effective treatment strategies for CRC and metastatic CRC (mCRC). MicroRNAs (miRs), small, single-stranded, noncoding RNAs, can post-transcriptionally regulate mRNA translation and trigger mRNA degradation. Recent studies have documented aberrant miR levels in patients with CRC or mCRC, and some miRs are reportedly associated with chemoresistance or radioresistance in CRC. Herein, we present a narrative review of the literature on the roles of oncogenic miRs (oncomiRs) and tumor suppressor miRs (anti-oncomiRs), some of which can be used to predict the responses of patients with CRC to chemotherapy or chemoradiotherapy. Moreover, miRs may serve as potential therapeutic targets because their functions can be manipulated using synthetic antagonists and miR mimics.</description><subject>5-Fluorouracil</subject><subject>Antagonists</subject><subject>Biomarkers</subject><subject>Biopsy</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemoradiotherapy</subject><subject>Chemoresistance</subject><subject>Chemotherapy</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Development and progression</subject><subject>DNA methylation</subject><subject>Environmental factors</subject><subject>Feces</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Kinases</subject><subject>Literature reviews</subject><subject>Malignancy</subject><subject>Management</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>MicroRNA</subject><subject>MicroRNAs</subject><subject>miRNA</subject><subject>Mortality</subject><subject>Oxaliplatin</subject><subject>Patients</subject><subject>Physiological aspects</subject><subject>Post-transcription</subject><subject>Radiation therapy</subject><subject>Radioresistance</subject><subject>Radiotherapy</subject><subject>Regulatory approval</subject><subject>Review</subject><subject>Survival</subject><subject>Therapeutic targets</subject><subject>Translation</subject><subject>Tumor markers</subject><subject>Tumor suppressor genes</subject><subject>Tumorigenesis</subject><subject>Vascular endothelial growth factor</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkk1v1DAQhiMEolXpmRuyxIXLtnacxAkXtER8SUupKjhbs_Zkd0o23trOVv0X_GS8u21pK-yD7fEz73jGk2WvBT-RsuGnBgaDPoiSl0KW9bPsMOcqn1RVUzx_sD_IjkO45GlIKVSlXmYHsmo4F2VzmP35Tsa7i7NpYBDYuUdLJtIG2UdyK_C_kz6jgZ1DJBxiYNcUl6x1vfNoIvSs3b2BXaBB2tCwYO0SVy4u0cP6hjm_P3uwdGd8z6bsDLyHXZgZxWSNo8eksSG8fpW96KAPeHy7HmW_Pn_62X6dzH58-dZOZxNT1E2cGA6VVYUFYTosirLOQdUCRIMqLwRWvLFqXnJQORTWctFZVXJMDM5R5HOQR9mHve56nK_QmpSdh16vPaW0b7QD0o9vBlrqhdtosa0kVyIpvLtV8O5qxBD1ioLBvocB3Rh0ruoqwbmQCX37BL10ox9SfluqFKoupPpHLaBHTUPnUmCzFdVTVQglm2andfIfKk2LKzJuwI6S_ZHD6d4hfXQIHrv7JAXX20bSTxopebx5WJt7_q5t5F8hVsa_</recordid><startdate>20230221</startdate><enddate>20230221</enddate><creator>Yang, I-Ping</creator><creator>Yip, Kwan-Ling</creator><creator>Chang, Yu-Tang</creator><creator>Chen, Yen-Cheng</creator><creator>Huang, Ching-Wen</creator><creator>Tsai, Hsiang-Lin</creator><creator>Yeh, Yung-Sung</creator><creator>Wang, Jaw-Yuan</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7705-2621</orcidid><orcidid>https://orcid.org/0000-0002-1645-2525</orcidid></search><sort><creationdate>20230221</creationdate><title>MicroRNAs as Predictive Biomarkers in Patients with Colorectal Cancer Receiving Chemotherapy or Chemoradiotherapy: A Narrative Literature Review</title><author>Yang, I-Ping ; Yip, Kwan-Ling ; Chang, Yu-Tang ; Chen, Yen-Cheng ; Huang, Ching-Wen ; Tsai, Hsiang-Lin ; Yeh, Yung-Sung ; Wang, Jaw-Yuan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c489t-c0a6d74da1cfe44582a781a19e7241e609d7b50a72a4dd01fd750ea78ebe12ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>5-Fluorouracil</topic><topic>Antagonists</topic><topic>Biomarkers</topic><topic>Biopsy</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemoradiotherapy</topic><topic>Chemoresistance</topic><topic>Chemotherapy</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Development and progression</topic><topic>DNA methylation</topic><topic>Environmental factors</topic><topic>Feces</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Kinases</topic><topic>Literature reviews</topic><topic>Malignancy</topic><topic>Management</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>MicroRNA</topic><topic>MicroRNAs</topic><topic>miRNA</topic><topic>Mortality</topic><topic>Oxaliplatin</topic><topic>Patients</topic><topic>Physiological aspects</topic><topic>Post-transcription</topic><topic>Radiation therapy</topic><topic>Radioresistance</topic><topic>Radiotherapy</topic><topic>Regulatory approval</topic><topic>Review</topic><topic>Survival</topic><topic>Therapeutic targets</topic><topic>Translation</topic><topic>Tumor markers</topic><topic>Tumor suppressor genes</topic><topic>Tumorigenesis</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, I-Ping</creatorcontrib><creatorcontrib>Yip, Kwan-Ling</creatorcontrib><creatorcontrib>Chang, Yu-Tang</creatorcontrib><creatorcontrib>Chen, Yen-Cheng</creatorcontrib><creatorcontrib>Huang, Ching-Wen</creatorcontrib><creatorcontrib>Tsai, Hsiang-Lin</creatorcontrib><creatorcontrib>Yeh, Yung-Sung</creatorcontrib><creatorcontrib>Wang, Jaw-Yuan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, I-Ping</au><au>Yip, Kwan-Ling</au><au>Chang, Yu-Tang</au><au>Chen, Yen-Cheng</au><au>Huang, Ching-Wen</au><au>Tsai, Hsiang-Lin</au><au>Yeh, Yung-Sung</au><au>Wang, Jaw-Yuan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MicroRNAs as Predictive Biomarkers in Patients with Colorectal Cancer Receiving Chemotherapy or Chemoradiotherapy: A Narrative Literature Review</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2023-02-21</date><risdate>2023</risdate><volume>15</volume><issue>5</issue><spage>1358</spage><pages>1358-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Colorectal cancer (CRC) is one of the most common malignancies and is associated with high mortality rates worldwide. The underlying mechanism of tumorigenesis in CRC is complex, involving genetic, lifestyle-related, and environmental factors. Although radical resection with adjuvant FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) chemotherapy and neoadjuvant chemoradiotherapy have remained mainstays of treatment for patients with stage III CRC and locally advanced rectal cancer, respectively, the oncological outcomes of these treatments are often unsatisfactory. To improve patients' chances of survival, researchers are actively searching for new biomarkers to facilitate the development of more effective treatment strategies for CRC and metastatic CRC (mCRC). MicroRNAs (miRs), small, single-stranded, noncoding RNAs, can post-transcriptionally regulate mRNA translation and trigger mRNA degradation. Recent studies have documented aberrant miR levels in patients with CRC or mCRC, and some miRs are reportedly associated with chemoresistance or radioresistance in CRC. Herein, we present a narrative review of the literature on the roles of oncogenic miRs (oncomiRs) and tumor suppressor miRs (anti-oncomiRs), some of which can be used to predict the responses of patients with CRC to chemotherapy or chemoradiotherapy. Moreover, miRs may serve as potential therapeutic targets because their functions can be manipulated using synthetic antagonists and miR mimics.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>36900159</pmid><doi>10.3390/cancers15051358</doi><orcidid>https://orcid.org/0000-0002-7705-2621</orcidid><orcidid>https://orcid.org/0000-0002-1645-2525</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2023-02, Vol.15 (5), p.1358 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10000071 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | 5-Fluorouracil Antagonists Biomarkers Biopsy Cancer Cancer therapies Care and treatment Chemoradiotherapy Chemoresistance Chemotherapy Colorectal cancer Colorectal carcinoma Development and progression DNA methylation Environmental factors Feces Genetic aspects Health aspects Kinases Literature reviews Malignancy Management Medical prognosis Medical research Metastases Metastasis MicroRNA MicroRNAs miRNA Mortality Oxaliplatin Patients Physiological aspects Post-transcription Radiation therapy Radioresistance Radiotherapy Regulatory approval Review Survival Therapeutic targets Translation Tumor markers Tumor suppressor genes Tumorigenesis Vascular endothelial growth factor |
| title | MicroRNAs as Predictive Biomarkers in Patients with Colorectal Cancer Receiving Chemotherapy or Chemoradiotherapy: A Narrative Literature Review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T18%3A39%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MicroRNAs%20as%20Predictive%20Biomarkers%20in%20Patients%20with%20Colorectal%20Cancer%20Receiving%20Chemotherapy%20or%20Chemoradiotherapy:%20A%20Narrative%20Literature%20Review&rft.jtitle=Cancers&rft.au=Yang,%20I-Ping&rft.date=2023-02-21&rft.volume=15&rft.issue=5&rft.spage=1358&rft.pages=1358-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers15051358&rft_dat=%3Cgale_pubme%3EA741739913%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2785178437&rft_id=info:pmid/36900159&rft_galeid=A741739913&rfr_iscdi=true |